HepQuant SHUNT Detects Portal Hypertension in Early Stages of Clinically Compensated Chronic Liver Disease

Amanda Wieland; Ohad Etzion; Rabab O Ali; Elliot Levy; David E Kleiner; Steve M Helmke; Theo Heller; Gregory T Everson

doi:10.1016/j.cgh.2021.04.030

HepQuant SHUNT Detects Portal Hypertension in Early Stages of Clinically Compensated Chronic Liver Disease

Clin Gastroenterol Hepatol. 2022 Apr;20(4):e890-e894. doi: 10.1016/j.cgh.2021.04.030. Epub 2021 Apr 22.

Authors

Amanda Wieland¹, Ohad Etzion², Rabab O Ali², Elliot Levy², David E Kleiner³, Steve M Helmke⁴, Theo Heller², Gregory T Everson⁵

Affiliations

¹ Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
² National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
³ Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland.
⁴ Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado; HepQuant LLC, Greenwood Village, Colorado.
⁵ Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado; HepQuant LLC, Greenwood Village, Colorado. Electronic address: greg.everson@hepquant.com.

Abstract

Physicians use portal pressure measurements in clinical practice and research but the methods are invasive, can cause complications, and are resource intensive.^1-3 Herein we describe preliminary findings of the minimally invasive HepQuant-SHUNT test in the diagnosis of portal hypertension in precirrhotic and compensated cirrhotic patients.

Publication types

Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Hypertension, Portal* / complications
Liver Cirrhosis / complications
Liver Cirrhosis / diagnosis
Liver Cirrhosis / surgery

Abstract

Publication types

MeSH terms

Grants and funding